Lion's Mane After Concussion: Can It Help Recovery?

Mushrooms & Brain Health / Cognition

40% BDNF increase from erinacine C after mild TBI in an animal model (Lee 2024, Antioxidants)

Lee and colleagues tested novel erinacines from lion's mane mycelium in a mild traumatic brain injury model and found erinacine C significantly increased BDNF by 40%, antioxidant enzymes by 45-80%, and activated Nrf2 in the cortex and sub-cortex.

Lee et al., Antioxidants, 2024

Nrf2 pathway

the master antioxidant regulator activated by erinacine C after mild TBI: the key mechanism

erinacines (mycelium)

erinacines cross the blood-brain barrier; hericenones from fruiting body are less relevant for TBI

no human trials

all evidence is animal preclinical; no randomized controlled trial on lion's mane for concussion exists

Lee et al., Antioxidants, 2024

View as image ↗

Concussion is one of the most common brain injuries, affecting tens of millions of people annually in sports, falls, vehicle accidents, and military contexts. There is no FDA-approved pharmaceutical that accelerates concussion recovery. Standard care is rest and symptom management. The absence of pharmacological options is why patients and families frequently seek supplements during recovery.

Lion's mane mushroom (Hericium erinaceus) has specific preclinical evidence relevant to concussion recovery. The mechanism is not generic "brain support" but a specific molecular pathway: erinacines from lion's mane mycelium activate the Nrf2 antioxidant response pathway that is directly implicated in the secondary neurological damage that follows the initial injury.

This article covers what the research shows for mild traumatic brain injury specifically, why mycelium matters more than fruiting body for this application, and what the evidence does not yet establish.

For the broader mushroom and brain health context, see Mushrooms and Cognitive Aging: Can They Protect Your Brain?. For the full TBI neuroprotective research overview across multiple mushroom species, see Mushrooms for Traumatic Brain Injury: Neuroprotective Research.

Key Takeaways

Lee and colleagues (Antioxidants, 2024) tested novel erinacines from Hericium erinaceus mycelium in a mild traumatic brain injury (mTBI) animal model and found erinacine C activated the Nrf2 pathway, increasing BDNF by 40%, catalase (CAT) by 80%, thioredoxin reductase (TrxR) by 80%, and SOD by 45% compared to controls
Nrf2 (nuclear factor erythroid 2-related factor 2) is the master regulator of the cellular antioxidant response and is directly implicated in the secondary neurological damage cascade that follows concussion; activating Nrf2 reduces oxidative damage to neurons during this critical window
Spangenberg and colleagues (Frontiers in Pharmacology, 2025) published the first systematic review of erinacine neuroprotective evidence across preclinical models, providing the most current and comprehensive synthesis of why erinacines are the primary neuroprotective compound class in lion's mane
Huang and colleagues (Scientific Reports, 2021) found that lion's mane mycelium and its bioactive compounds promoted oligodendrocyte maturation and increased myelin basic protein; oligodendrocytes produce myelin, the insulating sheath around nerve fibers that concussions disrupt
The distinction between erinacines (found in mycelium) and hericenones (found in fruiting body) is practically important: the mTBI Nrf2 pathway is activated by erinacines, which are confirmed to cross the blood-brain barrier; hericenones do not readily cross the barrier
No human clinical trial has tested lion's mane for concussion recovery; all evidence is from animal models; timing, dosage, and translation to human outcomes are unknown

What Happens in the Brain After a Concussion: The Secondary Injury Problem

The direct physical damage from a concussion (the primary injury) is often less damaging than what follows it. In the hours and days after a concussive impact, a secondary neurological cascade unfolds that can cause more harm than the original force.

The cascade has several interconnected components. The initial impact disrupts ionic gradients across neuronal membranes, triggering a metabolic crisis: neurons expend large amounts of energy trying to restore balance. Simultaneously, the mechanical disruption triggers microglial activation. Microglia are the brain's resident immune cells; when activated, they release inflammatory cytokines (including IL-1 beta, TNF-alpha, and IL-6) and reactive oxygen species (ROS) that damage neurons and disrupt neural circuits.

Oxidative stress is one of the most damaging elements of the secondary injury cascade. ROS damage neuronal membranes, mitochondrial function, and DNA. The brain's natural defense against oxidative stress is the Nrf2 pathway: when Nrf2 is activated, it triggers the production of antioxidant enzymes including superoxide dismutase (SOD), catalase (CAT), and thioredoxin reductase (TrxR). These enzymes neutralize the reactive oxygen species before they can damage neurons.

The practical implication: compounds that activate Nrf2 during the post-concussion window may reduce the secondary neurological damage that determines long-term recovery outcomes.

The Lee 2024 mTBI Study: The Most Relevant Research for Concussion

The most directly relevant study to mild concussion is a 2024 paper by Lee and colleagues in Antioxidants.^[1]

The study used a mild traumatic brain injury (mTBI) model, which is more analogous to sports concussion than the severe TBI models used in older research. The researchers tested novel erinacines isolated from Hericium erinaceus mycelium in both in vitro glial cells and in vivo mTBI animals.

The key quantitative findings:

BDNF (brain-derived neurotrophic factor) increased by 40% compared to LPS-treated controls. BDNF is the primary growth factor that supports neuronal survival, plasticity, and repair. Its reduction after concussion is associated with worse recovery outcomes.
Catalase (CAT) increased by 80%. Catalase is an antioxidant enzyme that converts hydrogen peroxide, a reactive oxygen species, into water and oxygen.
Thioredoxin reductase (TrxR) increased by 80%. TrxR is part of the thioredoxin antioxidant system that protects cellular proteins from oxidative damage.
Superoxide dismutase (SOD) increased by 45%. SOD neutralizes the superoxide radical, one of the primary sources of oxidative damage after neural injury.
Nrf2 expression was significantly induced in the cortex and sub-cortex of mTBI animals.

The Nrf2 induction is the mechanistic explanation for all the enzyme increases: erinacine C activated the Nrf2 transcription factor, which then turned on the genes encoding the antioxidant enzymes. The BDNF increase adds a neurotrophic (nerve-growth-promoting) benefit on top of the antioxidant effect.

Erinacines vs. Hericenones: The Form That Matters for Concussion

This distinction is practically important and almost never explained in consumer content.

Lion's mane contains two classes of neuroactive compounds with different chemical properties and different sources within the mushroom:

Erinacines are found primarily in the mycelium (the vegetative part of the fungus, not the visible mushroom). They are diterpenoid compounds that are small enough to cross the blood-brain barrier, which is the protective filter between the bloodstream and the brain. Because they cross this barrier, erinacines can directly interact with brain cells. The Lee 2024 mTBI study used erinacines from mycelium and found the Nrf2 activation in brain tissue, a result that requires the compounds to have reached the brain.

Hericenones are found in the fruiting body (the visible mushroom cap and stem). They are larger aromatic compounds that stimulate NGF (nerve growth factor) production in cell culture. Hericenones are more commonly covered in consumer content about lion's mane for cognitive function. However, they do not readily cross the blood-brain barrier in the same way, which limits their direct brain activity after oral consumption.

Li and colleagues published a 2018 review in Behavioural Neurology specifically on the neurohealth properties of erinacine-enriched HE mycelium, establishing the erinacine class as the primary neuroprotective compounds in lion's mane.^[3] The review covered NGF induction, neurogenesis, anti-apoptotic effects, and anti-inflammatory mechanisms attributable to the mycelium erinacine fraction.

The practical implication: for concussion recovery applications, where the mechanism involves Nrf2 activation in brain tissue, mycelium-derived products with high erinacine content are more relevant than fruiting body products. Standard fruiting body lion's mane supplements with high beta-glucan content are not the same product as erinacine-enriched mycelium.

For more detail on the distinction between these compound classes, see Hericenones and Erinacines: Lion's Mane's Brain-Boosting Compounds.

The Myelin Repair Angle: Oligodendrocyte Maturation

Concussions disrupt myelin, the protective fatty sheath that surrounds nerve fibers and enables efficient signal transmission. When myelin is damaged, signals travel more slowly or incorrectly, which may contribute to the cognitive fog, slowed processing, and coordination problems that characterize post-concussion syndrome.

Oligodendrocytes are the specialized cells in the central nervous system responsible for producing and maintaining myelin. Oligodendrocyte loss or dysfunction after concussion impairs the brain's capacity for myelin repair.

Huang and colleagues published a 2021 study in Scientific Reports testing whether Hericium erinaceus mycelium and its bioactive compounds promote oligodendrocyte maturation.^[4] The study found that lion's mane mycelium and its compounds promoted oligodendrocyte maturation and significantly increased myelin basic protein, the primary structural protein of myelin sheaths.

This oligodendrocyte-promoting activity adds a distinct mechanism to the erinacine picture: beyond reducing post-injury oxidative damage (via Nrf2), lion's mane may also support the remyelination process that is critical for functional recovery after concussion. These are complementary mechanisms: one reduces the neurological damage cascade, the other supports the structural repair process.

The Systematic Review: What Spangenberg 2025 Synthesizes

A 2025 systematic review by Spangenberg and colleagues in Frontiers in Pharmacology synthesized all preclinical erinacine neuroprotection evidence to date, producing the most current and authoritative overview of the mechanism by which lion's mane mycelium compounds protect neurons.^[2]

The Spangenberg 2025 systematic review established that erinacines are the primary active compounds for neuroprotection in lion's mane, distinct from the hericenones in fruiting bodies, and mapped the breadth of neuroprotective mechanisms across multiple disease models.

The systematic review is the academic authority for the current state of erinacine neuroprotection evidence. It synthesizes individual animal studies into a coherent evidence map and explicitly addresses the question of which compounds in lion's mane are responsible for which effects.

What the Evidence Does and Doesn't Say

What the preclinical research establishes:

Erinacine C from lion's mane mycelium activates the Nrf2 antioxidant pathway after mild TBI in an animal model, producing significant increases in BDNF and multiple antioxidant enzymes
Lion's mane mycelium compounds promote oligodendrocyte maturation and myelin basic protein production in cell culture
The mechanisms are relevant to the pathophysiology of concussion recovery: Nrf2 counteracts post-injury oxidative stress; oligodendrocyte promotion addresses myelin repair
Erinacines cross the blood-brain barrier and are the relevant compound class for brain-specific effects

What the evidence does not establish:

That lion's mane supplementation improves concussion recovery in humans
The optimal dose, timing (how soon after injury, how long to continue), and form for any potential human benefit
Whether the enzyme increase magnitudes seen in animals translate proportionally to humans
Any comparison with standard concussion management or other neuroprotective strategies in human clinical trials

No randomized controlled trial on lion's mane for concussion recovery exists. The evidence is entirely preclinical and should be understood as mechanistic rationale for further investigation, not as clinical guidance.

On the mycelium vs. fruiting body question: for concussion recovery specifically, the research basis is in erinacine-containing mycelium preparations, not in standard fruiting body extracts. The two products are different. Products that combine mycelium and fruiting body may provide broader bioactive coverage, but the TBI-relevant mechanism is specifically attributable to the erinacine fraction from mycelium.

For the broader picture of mushroom compounds and the neuroinflammation cascade after injury, see Mushroom Compounds and Brain Inflammation After Injury.

The Bottom Line

Lion's mane mushroom contains erinacines (in mycelium) that activate the Nrf2 antioxidant pathway, which is directly implicated in post-concussion secondary injury. Lee and colleagues (Antioxidants, 2024) found erinacine C in a mild TBI model increased BDNF by 40%, CAT and TrxR by 80%, and SOD by 45% via Nrf2 activation. Huang 2021 showed oligodendrocyte maturation and myelin basic protein increases. Spangenberg 2025 systematic review synthesizes the full erinacine neuroprotection evidence base. No human clinical trial on lion's mane for concussion exists. Mycelium (erinacine-rich) is more relevant than fruiting body for this application.

Frequently Asked Questions

Preclinical research shows erinacines from lion's mane mycelium activate the Nrf2 antioxidant pathway and increased BDNF by 40% in a mild TBI animal model (Lee 2024). The mechanism is relevant to concussion recovery because post-concussion oxidative stress is a primary driver of secondary brain damage. No human clinical trial exists. The evidence is animal preclinical and cannot be used to make clinical recommendations for concussion management.

No clinical evidence exists to answer this question. The animal studies do not establish timing windows that translate to human dosing guidance. Standard preclinical research tests compounds starting at time of injury or shortly after, but whether early administration produces different results than delayed administration in humans has not been studied. This is one of many questions that requires human clinical trials to answer.

Lion's mane contains two main classes of neuroactive compounds: erinacines (from mycelium), which activate the Nrf2 antioxidant pathway and stimulate BDNF production, confirmed to cross the blood-brain barrier; and hericenones (from fruiting body), which stimulate nerve growth factor production. Erinacines are more directly relevant to TBI and concussion contexts. Oligodendrocyte maturation (myelin repair) is an additional mechanism found in mycelium preparations.

In animal models, erinacines from lion's mane mycelium reduce neuroinflammation through Nrf2 pathway activation, which reduces oxidative stress and supports antioxidant enzyme production. The Lee 2024 mTBI study showed this specifically in a mild TBI context. Cordycepin from Cordyceps has also shown neuroinflammation-reducing effects in separate animal studies. No human neuroinflammation data after concussion exists for either mushroom.

Based on the preclinical evidence, mycelium with high erinacine content is more relevant for TBI and concussion applications. Erinacines are found in mycelium, cross the blood-brain barrier, and activated the Nrf2 pathway in the mTBI study. Fruiting body products are higher in hericenones, which are more focused on NGF stimulation and do not readily cross the blood-brain barrier. These are different products with different bioactive profiles; "lion's mane" on a label does not specify which is present.

Sources & References

1RTHM-01924·Lee, Kam-Fai et al. (2024). “The Cerebral Protective Effect of Novel Erinacines from Hericium erinaceus Mycelium on In Vivo Mild Traumatic Brain Injury Animal Model and Primary Mixed Glial Cells via Nrf2-Dependent Pathways..” Antioxidants (Basel.Study breakdown →PubMed →↩
2RTHM-02184·Spangenberg, E T et al. (2025). “Unveiling the role of erinacines in the neuroprotective effects of Hericium erinaceus: a systematic review in preclinical models..” Frontiers in pharmacology.Study breakdown →PubMed →↩
3RTHM-00973·Li, I-Chen et al. (2018). “Neurohealth Properties of Hericium erinaceus Mycelia Enriched with Erinacines..” Behavioural neurology.Study breakdown →PubMed →↩
4RTHM-00692·Huang, Hui-Ting et al. (2021). “Hericium erinaceus mycelium and its small bioactive compounds promote oligodendrocyte maturation with an increase in myelin basic protein..” Scientific reports.Study breakdown →PubMed →↩